Evidence map›Paper›PMID 39406735›Full record

ArticleNature communications2024

Centrioles are frequently amplified in early B cell development but dispensable for humoral immunity.

Marina A Schapfl, Gina M LoMastro, Vincent Z Braun, Maretoshi Hirai, Michelle S Levine, Eva Kiermaier, Verena Labi, Andrew J Holland, Andreas Villunger

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marina A SchapflInstitute for Developmental Immunology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0003-3764-9615
Gina M LoMastroDepartment of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Vincent Z BraunInstitute for Developmental Immunology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0009-0006-0858-3775
Maretoshi HiraiDepartment of Pharmacology, Kansai Medical University, Hirakata, Osaka, Japan.ORCID 0000-0001-6913-8655
Michelle S LevineDepartment of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Eva KiermaierLife and Medical Sciences Institute, Immune and Tumor Biology, University of Bonn, Bonn, Germany.ORCID 0000-0001-6165-5738
Verena LabiInstitute for Developmental Immunology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0001-7538-1520
Andrew J HollandDepartment of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-3728-6367
Andreas VillungerInstitute for Developmental Immunology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria. andreas.villunger@i-med.ac.at.ORCID 0000-0001-8259-4153

Funding

Centrosome biogenesis and copy number controlR01GM114119 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI CORMACK, BRENDAN · 2015 to 2023
$3.3M
The role of TRIM37 in driving tumorigenesis and cancer-specific vulnerability to PLK4 inhibitionR01CA266199 · NCI · JOHNS HOPKINS UNIVERSITY · PI Sergi Regot · 2022 to 2026
$2.7M
Molecular mechanism that suppresses the proliferation of cells with supernumerary centriolesR01GM133897 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI CORMACK, BRENDAN · 2019 to 2022
$1.9M
Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) 10.55776/DOC82Deutsche Forschungsgemeinschaft (German Research Foundation) EXC 2151 - 390873048EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) ERC_AdG_787171NCI NIH HHS R01 CA266199NIGMS NIH HHS R01 GM114119NIGMS NIH HHS R01 GM133897
6 · The paper itself

Abstract

Centrioles define centrosome structure and function. Deregulation of centriole numbers can cause developmental defects and cancer. The p53 tumor suppressor limits the growth of cells lacking or harboring additional centrosomes and can be engaged by the "mitotic surveillance" or the "PIDDosome pathway", respectively. Here, we show that early B cell progenitors frequently present extra centrioles, ensuing their high proliferative activity and related DNA damage. Extra centrioles are efficiently cleared during B cell maturation. In contrast, centriole loss upon Polo-like kinase 4 (Plk4) deletion causes apoptosis and arrests B cell development. This defect can be rescued by co-deletion of Usp28, a critical component of the mitotic surveillance pathway, that restores cell survival and maturation. Centriole-deficient mature B cells are proliferation competent and mount a humoral immune response. Our findings imply that progenitor B cells are intolerant to centriole loss but permissive to centriole amplification, a feature potentially facilitating their malignant transformation.

Indexed as

B-LymphocytesCentriolesImmunity, HumoralProtein Serine-Threonine KinasesAnimalsApoptosisCell DifferentiationCell ProliferationDNA DamageMiceMice, Inbred C57BLMice, KnockoutProtein Serine-Threonine Kinases

Identifiers

PMID39406735
PMCPMC11480410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.